Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine in Pediatric MDS and JMML
NCT02447666Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2015
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of azacitidine in myelodysplastic syndrome (MDS), juvenile myelomonocytic leukemia (JMML), sponsored by Celgene Corporation. Started Sep 2015; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on NCT02447666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02447666.